VASTRA FROLUNDA, Sweden--(BUSINESS WIRE)--Regulatory News: This is information which Artimplant (STO:ARTIB) shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on December 27, 2007 at 08:45 AM. The biomaterials company Artimplant signs licensing agreement with Small Bone Innovations, Inc. (SBi) for all joints in the hand and wrist domain. The license is exclusive and global (except for the Nordic countries) and covers resurfacing with Artelon®, a concept that contributes to regenerating function in joints that have degenerated functionality due to osteoarthritis. Artimplant will receive an up-front payment of USD 500,000 for the license and SBi will absorb all expenses for development and regulatory registration of new Artelon® implants for the hand and wrist. Moreover, the parties have granted each other an option to transfer the ownership of existing product clearances to SBi for an aggregate amount of USD 400,000.
